ROME — Two injectable drugs with mitochondrial-stabilizing properties, risuteganib and elamipretide, show promise in reversing vision loss in dry age-related macular degeneration.
“Both drugs have shown threshold OCT characteristics that predict BCVA response to treatment, and that’s the important message,” Baruch D. Kuppermann, MD, PhD, said at the FLORetina-ICOOR meeting.
In a phase 2a trial, 48% of the patients who received intravitreal injections of risuteganib (Allegro Ophthalmics) at baseline and week 16, with analysis at 28 weeks, achieved the primary endpoint of